TrialPloS one2014

A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.

Aaron D Schimmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.